ACROLIMUS PR 3 MG

Nazione: Israele

Lingua: inglese

Fonte: Ministry of Health

Compra

Principio attivo:

TACROLIMUS AS MONOHYDRATE

Commercializzato da:

TEVA ISRAEL LTD

Codice ATC:

L04AD02

Forma farmaceutica:

CAPSULES PROLONGED RELEASE

Composizione:

TACROLIMUS AS MONOHYDRATE 3 MG

Via di somministrazione:

PER OS

Tipo di ricetta:

Required

Prodotto da:

TEVA ISRAEL LTD, ISRAEL

Area terapeutica:

TACROLIMUS

Indicazioni terapeutiche:

- Prophylaxis of transplant rejection in adult kidney or liver allograft recipients.- Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult kidney or liver allograft recipient patients.

Data dell'autorizzazione:

2022-07-11

Foglio illustrativo

                                PATIENT LEAFLET IN ACCORDANCE
WITH THE PHARMACISTS’
REGULATIONS (PREPARATIONS) – 1986
THE MEDICINE IS DISPENSED WITH A
DOCTOR’S PRESCRIPTION ONLY
ACROLIMUS PR
1 MG
EXTENDED
RELEASE CAPSULES
COMPOSITION:
Each capsule
contains:
Tacrolimus
(as monohydrate)
1 mg
ACROLIMUS PR
0.5 MG
EXTENDED
RELEASE CAPSULES
COMPOSITION:
Each capsule
contains:
Tacrolimus
(as monohydrate)
0.5 mg
ACROLIMUS PR
5 MG
EXTENDED
RELEASE CAPSULES
COMPOSITION:
Each capsule
contains:
Tacrolimus
(as monohydrate)
5 mg
ACROLIMUS PR
3 MG
EXTENDED
RELEASE CAPSULES
COMPOSITION:
Each capsule
contains:
Tacrolimus
(as monohydrate)
3 mg
For information regarding inactive ingredients
and allergens, see section 2 – “Important
information about some ingredients of
the medicine” and section 6 – “Additional
information”.
READ THE ENTIRE LEAFLET CAREFULLY BEFORE
USING THE MEDICINE. This leaflet contains
concise information about the medicine. If
you have additional questions, refer to the
doctor or the pharmacist.
This medicine has been prescribed for you.
Do not pass it on to others. It may harm them
even if it seems to you that their medical
condition is similar.
The medicine is not intended for children and
adolescents under the age of 18.
1. WHAT IS THE MEDICINE INTENDED
FOR?
Prevention of transplant rejection after kidney
or liver transplant.
Treatment of transplant rejection, after kidney
or liver transplant, when there is resistance to
other immunosuppressive medicines.
THERAPEUTIC CLASS: Immunosuppressants.
2. BEFORE USING THE MEDICINE
DO NOT USE THIS MEDICINE IF:
• You are sensitive (allergic) to tacrolimus
or to any of the other ingredients this
medicine contains (see section 6 –
“Additional information”).
• You are sensitive (allergic) to sirolimus
or to macrolide antibiotics (such as
erythromycin, clarithromycin, josamycin).
SPECIAL WARNINGS REGARDING THE USE OF
THE MEDICINE
Some tacrolimus medicines for immediate
release and for sustained release contain the
same active ingredient, tacrolimus. Acrolimus
PR capsules are s
                                
                                Leggi il documento completo
                                
                            

Documenti in altre lingue

Foglio illustrativo Foglio illustrativo arabo 16-03-2023
Foglio illustrativo Foglio illustrativo ebraico 16-03-2023

Cerca alert relativi a questo prodotto

Visualizza cronologia documenti